Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
出版年份 2014 全文链接
标题
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
作者
关键词
<sup>177</sup>Lu-Octreotate, Neuroendocrine, 5-FU chemotherapy, Response, Predictive factors, Survival
出版物
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 41, Issue 10, Pages 1831-1844
出版商
Springer Nature
发表日期
2014-05-20
DOI
10.1007/s00259-014-2788-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
- (2013) Robert L. Fine et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion
- (2013) Raghava Kashyap et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence
- (2013) Davide Campana et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
- (2013) John J. Zaknun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
- (2013) Amir Sabet et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Systemic Therapeutic Options for Carcinoid
- (2013) Marianne Pavel et al. SEMINARS IN ONCOLOGY
- Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors
- (2013) Christos Toumpanakis et al. SEMINARS IN ONCOLOGY
- Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
- (2012) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Lutetium-labelled peptides for therapy of neuroendocrine tumours
- (2012) B. L. R. Kam et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Yttrium-labelled peptides for therapy of NET
- (2012) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
- (2012) Linda Villard et al. JOURNAL OF CLINICAL ONCOLOGY
- The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable
- (2011) T.W. Barber et al. EJSO
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- (2011) Jaap J M Teunissen et al. ENDOCRINE-RELATED CANCER
- The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
- (2011) Jean-Mathieu Beauregard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
- (2011) Jolanta Kunikowska et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
- (2011) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate
- (2011) S. Khan et al. JOURNAL OF NUCLEAR MEDICINE
- Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET
- (2011) Dorota Pach et al. RADIOTHERAPY AND ONCOLOGY
- 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
- (2010) Michael Garkavij et al. CANCER
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
- (2010) Daniel Hubble et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
- (2010) Phillip G. Claringbold et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
- (2010) M. van Essen et al. JOURNAL OF NUCLEAR MEDICINE
- High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience
- (2009) Grace Kong et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started